Immunohistochemical Analysis of Drug Resistanceassociated Proteins in Ovarian Carcinomas
作者： Doris Mayr , Uwe Pannekamp , Gustavo Bruno Baretton , Martina Gropp , Werner Meier
DOI: 10.1016/S0344-0338(00)80048-5
关键词:
摘要: Loss of function the tumor suppressor gene p53, increased expression glutathione-S-transferase pi (GST7pi) and major vault protein are involved in drug resistance ovarian carcinomas. However, a study comparing these factors has not yet been performed. Therefore, paraffin-embedded material 213 tumors with well-documented follow-up was used for immunohistochemical analysis p53 protein, GSTpi, (antibodies LRP-56, LMR-5). Forty-six percent cases showed nuclear accumulation. Strong immunoreactivity LMR-5 seen 50%, 36%, 47%, respectively. positivity most often found serous carcinomas (p 2 cm, GSTpi correlated an adverse outcome = 0.01 p 0.04 GSTpi). LRP-56 or staining associated tendency towards poorer prognosis, without reaching statistical significance. In multivariate FIGO III, only residual disease proved to be independent prognostic factors. Our observations confirm significance accumulation Only significantly resistance.
elsevier.com
sci-hub.se 参考文章(24)
M. J. Flens, G. L. Scheffer, G. A. Meijer, P. van der Valk, R. J. Scheper, M. A. Izquierdo, A. B. Schroeijers, Immunohistochemical detection of the human major vault protein LRP with two monoclonal antibodies in formalin-fixed, paraffin-embedded tissues. American Journal of Pathology. ,vol. 152, pp. 373- 378 ,(1998)
J. Kupryjanczyk, A. D. Thor, R. Beauchamp, V. Merritt, S. M. Edgerton, D. A. Bell, D. W. Yandell, p53 gene mutations and protein accumulation in human ovarian cancer Proceedings of the National Academy of Sciences of the United States of America. ,vol. 90, pp. 4961- 4965 ,(1993) , 10.1073/PNAS.90.11.4961
S.B. Kaye, M. Piccart, M. Aapro, P. Francis, J. Kavanagh, Phase II Trials of Docetaxel (Taxotere@) in Advanced Ovarian Cancer-an Updated Overview European Journal of Cancer. ,vol. 33, pp. 2167- 2170 ,(1997) , 10.1016/S0959-8049(97)00363-8
CV Christodoulou, AG Eliopoulos, LS Young, L Hodgkins, DR Ferry, DJ Kerr, Anti-proliferative activity and mechanism of action of titanocene dichloride. British Journal of Cancer. ,vol. 77, pp. 2088- 2097 ,(1998) , 10.1038/BJC.1998.352
Rosella Silvestrini, Maria Grazia Daidone, Silvia Veneroni, Elvira Benini, Giovanna Scarfone, Flavia Zanaboni, Antonella Villa, Mauro Presti, Saverio Danese, Giorgio Bolis, The clinical predictivity of biomarkers of stage III-IV epithelial ovarian cancer in a prospective randomized treatment protocol. Cancer. ,vol. 82, pp. 159- 167 ,(1998) , 10.1002/(SICI)1097-0142(19980101)82:1<159::AID-CNCR20>3.0.CO;2-0
D. P. Lane, p53, guardian of the genome Nature. ,vol. 358, pp. 15- 16 ,(1992) , 10.1038/358015A0
P Sarhanis, C Redman, C Perrett, K Brannigan, RN Clayton, P Hand, C Musgrove, V Suarez, P Jones, AA Fryer, WE Farrell, RC Strange, Epithelial ovarian cancer: influence of polymorphism at the glutathione S -transferase GSTM1 and GSTT1 loci on p53 expression British Journal of Cancer. ,vol. 74, pp. 1757- 1761 ,(1996) , 10.1038/BJC.1996.626
J Holford, SY Sharp, BA Murrer, M Abrams, LR Kelland, In vitro circumvention of cisplatin resistance by the novel sterically hindered platinum complex AMD473. British Journal of Cancer. ,vol. 77, pp. 366- 373 ,(1998) , 10.1038/BJC.1998.59
Lloyd R. Kelland, New platinum antitumor complexes Critical Reviews in Oncology Hematology. ,vol. 15, pp. 191- 219 ,(1993) , 10.1016/1040-8428(93)90042-3
Shin-Ichi Hamada, Masaharu Kamada, Hiroyuki Furumoto, Tsutomu Hirao, Toshihiro Aono, Expression of glutathione S-transferase-π in human ovarian cancer as an indicator of resistance to chemotherapy Gynecologic Oncology. ,vol. 52, pp. 313- 319 ,(1994) , 10.1006/GYNO.1994.1055